PFE Pfizer Inc. (NYSE) Market Closed 30 Jan 2026: $26.44 stock ahead of earnings
PFE stock closed at $26.44 on 30 Jan 2026 as investors brace for Pfizer Inc.’s Q4 earnings release. The company reports after the close on 03 Feb 2026, and expectations center on revenue mix, Paxlovid demand, and recent deal activity. Volume ended at 47,193,118 shares, signaling above-normal interest versus a 50-day average of 25.45. Traders will watch guidance, margin commentary, and any update on the company’s recent capital deployment for signs of an earnings-driven re-rate.
Earnings preview: what to watch in the PFE stock report
Pfizer reports results on 03 Feb 2026 and the main items for PFE stock are revenue trends and EPS drivers. Analysts will focus on COVID product sales, Paxlovid volumes, and Comirnaty revenue compared with prior quarters. Management guidance and one-off items from recent M&A or collaborations could move the share price quickly. Recent headlines around CEO capital plans have already nudged sentiment higher, per market coverage MarketBeat.
PFE stock valuation and price targets
Pfizer trades at PE 15.37 with EPS 1.72, a price-to-book near 1.62, and a dividend yielding 6.50%. Our practical price band: conservative $24.00, base $28.00, bullish $32.00. The base target implies 5.90% upside from $26.44. Targets reflect steady cash flow, payout risk, and sector multiples in Healthcare. Use the PE multiple and free cash flow metrics to judge moves after earnings.
Financials and key metrics that drive PFE stock
Pfizer shows revenue per share 11.04, free cash flow per share 1.83, and book value per share 16.38. Net debt versus EBITDA is ~2.85x, interest coverage is 6.47x, and payout ratio sits near 0.99, underscoring a high dividend commitment. These metrics help explain why PFE stock trades with a modest valuation and why dividend sustainability will be central to investor reaction to the earnings print.
Technicals and trading signals for PFE stock
Price action finished the day near the session high at $26.47 with RSI 54.16, MACD histogram slight positive, and ATR 0.48. Short-term momentum is neutral; Bollinger bands show tight volatility between 24.54 and 26.03. Average volume remains elevated at 63,444,259, so expect larger moves on earnings. Traders should watch support at $25.90 and resistance near the 52-week high $27.69.
Risks and opportunities affecting PFE stock
Key risks include softer-than-expected COVID product sales, margin pressure from pricing, and execution delays in the pipeline. Upside opportunities are stronger Paxlovid uptake, favorable margin commentary, and successful integration of any deals announced earlier this month. Sector dynamics in Healthcare and defensive demand can dampen volatility but also cap multi-quarter rallies for PFE stock.
Meyka grade and forecast for PFE stock
Meyka AI rates PFE with a score out of 100: 69.95 / Grade B / Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus, and forecasts. Analyst sentiment is mixed: 4 Buy, 9 Hold, 1 Sell. Meyka AI’s forecast model projects a monthly price of $24.96 and a yearly price of $23.46, compared with the current $26.44. These model outcomes reflect a modest downside risk if earnings disappoint. Forecasts are model-based projections and not guarantees. See Reuters coverage for broader market context Reuters.
Final Thoughts
Pfizer enters earnings season with PFE stock at $26.44 and mixed signals from valuation and cash flow metrics. Short-term market reaction will hinge on guidance, Paxlovid and Comirnaty revenue detail, and any commentary on capital allocation. Meyka AI’s model projects a monthly target of $24.96 (implied downside -5.60%) and a yearly target of $23.46 (implied downside -11.27%). Our central price target of $28.00 assumes steady patient-care demand and neutral margin trends, giving roughly 5.90% upside. Investors seeking income should weigh the 6.50% dividend yield against payout risk, and traders should monitor volume and support at $25.90. For a quick reference on quotes and live coverage visit Meyka’s PFE page at Meyka PFE stock page. Remember, forecasts are model-based projections and not guarantees.
FAQs
When does Pfizer report earnings and why does it matter for PFE stock?
Pfizer reports after the close on 03 Feb 2026. The earnings release matters for PFE stock because management guidance, Paxlovid sales, and margin details can change short-term valuation and trading volume.
What valuation metrics should investors check for PFE stock?
Key metrics for PFE stock are PE 15.37, EPS 1.72, price-to-book 1.62, and free cash flow yield near 6.90%. These show moderate valuation and income characteristics.
What is Meyka AI’s rating and price view for PFE stock?
Meyka AI rates PFE 69.95 / Grade B / HOLD. The model baseline target is $28.00 with forecasts of $24.96 monthly and $23.46 yearly. These are projections, not guarantees.
What are the main risks that could hurt PFE stock after earnings?
Main risks for PFE stock include weaker Paxlovid demand, lower vaccine revenue, margin compression, and disappointing guidance. Any surprise on capital allocation or regulatory news can amplify moves.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
